Executive Summary

SOLAR 2026 (Steatosis, Obesity, Liver Disease Advances In Clinical Research) is a groundbreaking global conference designed to explore and address the complex interconnections among liver disease, metabolic syndrome, obesity, and other emerging therapeutic areas.

The inaugural event will take place from Thursday, June 25 to Saturday, June 27, 2026, at the Fairmont El San Juan Hotel in Puerto Rico.

This unique educational summit will emphasize the shared etiologies and clinical challenges across liver disease, obesity, and metabolic dysfunction. Its core mission is to deliver high-quality education, review current research practices, explore scientific innovations, and translate new knowledge into improved clinical outcomes and patient care.

Guided by expert course directors, the conference will bring together clinicians, academic researchers, and representatives from the pharmaceutical industry for a dynamic and collaborative scientific program. Sessions will highlight the latest clinical and scientific breakthroughs and explore advancements in diagnostics, technology, and strategies to overcome the challenges of drug development.

Participants will also gain valuable insights into the clinical trial landscape, including trial design, execution, and novel non-invasive testing strategies. Continuing Medical Education (CME) symposiums will be integrated into each scientific track, allowing physicians, nurses, pharmacists, and advanced practice providers to earn credits based on their participation.

Course Directors & Co-Chair

Liver Scientific Committee

Becky Taub, MD

Madrigal Pharmaceuticals

Belle Vivica van Rosmalen, MD

Eli Lilly Pharmaceutical

Brian P. Lee, MD

USC Keck School of Medicine

Gene Im, MD

Columbia University

Jane Hsiao, PhD

OPKO

Scott Friedman, MD

Mount Sinai Institute for Liver Research

Jörn Schattenberg, MD

Saarland University Medical Center

Juan Pablo Arab, MD

Virginia Commonwealth University School of Medicine

Kitty Yale

Akero Therapeutics Biopharmaceutical

Lily Dara, MD

USC Keck School of Medicine

Mary Rinella, MD

University of Chicago

Meena Bansal, MD

Icahn School of Medicine at Mount Sinai

Naga Chalasani, MD

Indiana University School of Medicine

Nikhil Vergis, MD

GSK Biopharmaceutical

Norah Terrault, MD

USC Keck School of Medicine

Raj Vuppalanchi, MD

Indiana University School of Medicine

Ramy Younes, MD

Boehringer Ingelheim Pharmaceutical

Rashmee Patil, MD

Pinnacle Clinical Research

Obesity Scientific Board Committee

Carel le Roux, MBChB, PhD

University College Dublin

Ildiko Lingvay, MD, MPH, MSCS

University of Texas, Southwestern Medical Center at Dallas, TX

Domenica Rubino, MD

Washington Center for Weight Management and Research

Layla AbuShamat, MD

Baylor College of Medicine

Abd Tahrani, MD, PhD

University of Birmingham (UK)

Isabel Kloer, MD, MSc

Boehringer Ingelheim International GmbH, Ingelheim, Germany

Julia Dunn, MD, MSc, DABOM

Eli Lilly and Company

Georgios Dimitriadis, MD, MSc, PhD, FRCP

Eli Lilly and Company

Be the first to receive conference updates!

Click button below to experience the Early-Bird Pop-up sample.
The Approved pop-up will be triggered to pop everytime a user visits this landing page (once per visit).

This section is for reference only and will be deleted.

Connecting liver, obesity, and metabolic science to improve patient care.

This conference looks at the bigger picture—how liver disease, obesity, and metabolic dysfunction intertwine. It creates a space where clinicians, researchers, and industry experts can break silos, share insights, and shape the future of care together. By weaving cutting-edge science with real-world clinical strategies, it challenges participants to rethink how breakthroughs move from the lab to the patient.